Use of MRI Radiomics Models in Evaluating the Low HER2 Expression in Breast Cancer

被引:2
作者
Li, Hao [1 ]
Hou, Yan [1 ]
Xue, Lin-Yan [2 ]
Fan, Wen-Long [2 ]
Gao, Bu-Lang [1 ]
Yin, Xiao-Ping [1 ,3 ]
机构
[1] Hebei Univ, Affiliated Hosp, Dept Radiol, Hebei Key Lab precise imaging inflammat related tu, 212 Eastern Yuhua Rd, Baoding 071000, Hebei, Peoples R China
[2] Hebei Univ, Coll Qual & Tech Supervis, 180 Wusi East Rd, Baoding 071000, Hebei, Peoples R China
[3] Hebei Univ, Affiliated Hosp, Dept Radiol, 212 Eastern Yuhua Rd, Baoding 071000, Hebei, Peoples R China
关键词
Radiomics; Breast cancer; MRI; HER2; expression; CHEMOTHERAPY;
D O I
10.2174/0115734056234429240426181002
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective To investigate the magnetic resonance imaging (MRI) radiomics models in evaluating the human epidermal growth factor receptor 2(HER2) expression in breast cancer.Materials and Methods The MRI data of 161 patients with invasive ductal carcinoma (non-special type) of breast cancer were retrospectively collected, and the MRI radiomics models were established based on the MRI imaging features of the fat suppression T2 weighted image (T2WI) sequence, dynamic contrast-enhanced (DCE)-T1WIsequence and joint sequences. The T-test and the least absolute shrinkage and selection operator (LASSO) algorithm were used for feature dimensionality reduction and screening, respectively, and the random forest (RF) algorithm was used to construct the classification model.Results The model established by the LASSO-RF algorithm was used in the ROC curve analysis. In predicting the low expression state of HER2 in breast cancer, the radiomics models of the fat suppression T2WI sequence, DCE-T1WI sequence, and the combination of the two sequences showed better predictive efficiency. In the receiver operating characteristic (ROC) curve analysis for the verification set of low, negative, and positive HER2 expression, the area under the ROC curve (AUC) value was 0.81, 0.72, and 0.62 for the DCE-T1WI sequence model, 0.79, 0.65 and 0.77 for the T2WI sequence model, and 0.84, 0.73 and 0.66 for the joint sequence model, respectively. The joint sequence model had the highest AUC value.Conclusions The MRI radiomics models can be used to effectively predict the HER2 expression in breast cancer and provide a non-invasive and early assistant method for clinicians to formulate individualized and accurate treatment plans.
引用
收藏
页数:17
相关论文
共 43 条
[1]   Ensemble Feature Learning of Genomic Data Using Support Vector Machine [J].
Anaissi, Ali ;
Goyal, Madhu ;
Catchpoole, Daniel R. ;
Braytee, Ali ;
Kennedy, Paul J. .
PLOS ONE, 2016, 11 (06)
[2]   Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)-Positive Breast Cancer [J].
Braman, Nathaniel ;
Prasanna, Prateek ;
Whitney, Jon ;
Singh, Salendra ;
Beig, Niha ;
Etesami, Maryam ;
Bates, David D. B. ;
Gallagher, Katherine ;
Bloch, B. Nicolas ;
Vulchi, Manasa ;
Turk, Paulette ;
Bera, Kaustav ;
Abraham, Jame ;
Sikov, William M. ;
Somlo, George ;
Harris, Lyndsay N. ;
Gilmore, Hannah ;
Plecha, Donna ;
Varadan, Vinay ;
Madabhushi, Anant .
JAMA NETWORK OPEN, 2019, 2 (04)
[3]   Four-Dimensional Machine Learning Radiomics for the Pretreatment Assessment of Breast Cancer Pathologic Complete Response to Neoadjuvant Chemotherapy in Dynamic Contrast-Enhanced MRI [J].
Caballo, Marco ;
Sanderink, Wendelien B. G. ;
Han, Luyi ;
Gao, Yuan ;
Athanasiou, Alexandra ;
Mann, Ritse M. .
JOURNAL OF MAGNETIC RESONANCE IMAGING, 2023, 57 (01) :97-110
[4]   Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set [J].
Cain, Elizabeth Hope ;
Saha, Ashirbani ;
Harowicz, Michael R. ;
Marks, Jeffrey R. ;
Marcom, P. Kelly ;
Mazurowski, Maciej A. .
BREAST CANCER RESEARCH AND TREATMENT, 2019, 173 (02) :455-463
[5]   The Impact of Normalization Approaches to Automatically Detect Radiogenomic Phenotypes Characterizing Breast Cancer Receptors Status [J].
Castaldo, Rossana ;
Pane, Katia ;
Nicolai, Emanuele ;
Salvatore, Marco ;
Franzese, Monica .
CANCERS, 2020, 12 (02)
[6]   Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: how to speed it up? [J].
Curigliano, Giuseppe ;
Criscitiello, Carmen ;
Andre, Fabrice ;
Colleoni, Marco ;
Di Leo, Angelo .
ECANCERMEDICALSCIENCE, 2013, 7
[7]   Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies [J].
Dunton, Kyle ;
Vondeling, Gerard ;
Hancock, Elizabeth ;
Petrou, Margaret ;
Burn, Oliver ;
Paine, Abby .
TARGETED ONCOLOGY, 2022, 17 (06) :655-663
[8]   The Exciting New Field of HER2-Low Breast Cancer Treatment [J].
Eiger, Daniel ;
Agostinetto, Elisa ;
Saude-Conde, Rita ;
de Azambuja, Evandro .
CANCERS, 2021, 13 (05) :1-18
[9]   PREDICTIVE SAMPLE REUSE METHOD WITH APPLICATIONS [J].
GEISSER, S .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1975, 70 (350) :320-328
[10]   HER2DX genomic test in HER2-positive/hormone receptorpositive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial [J].
Guarneri, Valentina ;
Braso-Maristany, Fara ;
Vittoria Dieci, Maria ;
Griguolo, Gaia ;
Pare, Laia ;
Marin-Aguilera, Mercedes ;
Miglietta, Federica ;
Bottosso, Michele ;
Alberto Giorgi, Carlo ;
Blasco, Paula ;
Castillo, Oleguer ;
Galvan, Patricia ;
Vivancos, Ana ;
Villagrasa, Patricia ;
Parker, Joel S. ;
Perou, Charles M. ;
Conte, PierFranco ;
Prat, Aleix .
EBIOMEDICINE, 2022, 85